Invention Grant
US09567317B2 Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
有权
包括尼罗替尼和选择的共晶体形成剂的多组分结晶体系
- Patent Title: Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
- Patent Title (中): 包括尼罗替尼和选择的共晶体形成剂的多组分结晶体系
-
Application No.: US14433147Application Date: 2013-10-16
-
Publication No.: US09567317B2Publication Date: 2017-02-14
- Inventor: Tiziana Chiodo , Andreas Hafner , Tobias Hintermann , Beate Salvador , Martin Szelagiewicz , Fritz Blatter , Eva Roedel , Marcus Vossen
- Applicant: BASF SE
- Applicant Address: DE Ludwigshafen
- Assignee: BASF SE
- Current Assignee: BASF SE
- Current Assignee Address: DE Ludwigshafen
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: EP12189264 20121019; EP13167657 20130514
- International Application: PCT/EP2013/071580 WO 20131016
- International Announcement: WO2014/060449 WO 20140424
- Main IPC: C07D401/14
- IPC: C07D401/14
Abstract:
The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
Public/Granted literature
- US20150246901A1 MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS Public/Granted day:2015-09-03
Information query
